Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSA3-Biofusion
- Development stage
- Preclinical
- Lead developer
- Vac4All
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
LSA3-Biofusion (DG729) is a next-generation pre-erythrocytic malaria vaccine candidate developed by Vac4All in collaboration with Sanofi. It is a protein subunit vaccine based on the Biofusion platform, specifically designed to target the Liver-Stage Antigen-3 (LSA3) of *Plasmodium falciparum*. The vaccine aims to prevent malaria by blocking the infection during the liver stage through interferon-gamma-associated immune activity, thereby preventing the parasite from entering the blood stage where clinical symptoms occur. Part of the STOPMAL program, LSA3-Biofusion is currently in the preclinical and IND-enabling phase, with plans to advance into Phase 1a and Phase 2a controlled human malaria infection (CHMI) trials.
- Other names
- DG729DG-729DG 729
02
Targets
LSA-3 (Plasmodium falciparum liver-stage antigen 3)
Beyond the preview
Go deeper on LSA3-Biofusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSA3-Biofusion.